DP
INDV icon

Diadema Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Diadema Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Buy
71,376
+54,056
+312% +$1.79M 0.37% 58
2025
Q4 		$621K Sell
17,320
-236,932
-93% -$7.23M 0.11% 107
2025
Q3 		$6.13M Buy
+254,252
New +$5.32M 1.57% 20

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Diadema Partners's INDV Position: Q1 2026 in Review

Diadema Partners increased its Indivior Pharmaceuticals (INDV) stake by 312% in Q1 2026, buying an estimated $1.79M and bringing the position to 71,376 shares worth $2.18M. The position accounts for 0.37% of the portfolio, ranked #58.

Diadema Partners first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.13M in Q3 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Diadema Partners held 71,376 shares of Indivior Pharmaceuticals worth $2.18M as of Q1 2026.
  • Diadema Partners bought 54,056 Indivior Pharmaceuticals shares in Q1 2026, an estimated $1.79M.
  • Indivior Pharmaceuticals made up 0.37% of Diadema Partners's portfolio in Q1 2026, its #58 holding.
  • Diadema Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Diadema Partners's Indivior Pharmaceuticals position peaked at $6.13M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.